Scoped engagements, not retainers you forget about.

Before a Phase 3 reads out, the question worth asking is whether it was ever designed to succeed in a way that translates to an approvable, commercially meaningful label. This review covers:

• Endpoint selection and whether it aligns with precedent FDA approvals in the indication
• Statistical plan — power, event-driven vs. fixed-timepoint design, interim analysis structure
• Control arm appropriateness and enrollment feasibility given the target population
• Comparison against the competitive and standard-of-care landscape at expected readout

Topline press releases are written to be read favorably. A same-day clinical read separates a genuine signal from a subgroup analysis doing a lot of work, and flags what a fuller data presentation (ASH, ASCO, a peer-reviewed publication) is likely to add or subtract.

• Efficacy magnitude in context of historical controls, not just the p-value
• Safety signal assessment — what's expected-class-effect vs. genuinely new
• What's missing from the press release and why that might matter

A clean Phase 3 result from a company with twelve weeks of cash and a maturing convertible note is a different investment than the same result from a well-funded sponsor. This overlay covers:

• Cash runway against disclosed and reasonably inferred spend
• Dilution risk from outstanding warrants, ATMs, and financing structures already in place
• Going-concern language and what specifically is driving it
• Whether the balance sheet can plausibly fund the company through commercialization, or only to the next data point

Designations like Fast Track, Breakthrough Therapy, and Orphan Drug get reported as milestones. Each carries a specific, limited set of practical benefits. This assessment lays out what a given designation actually changes for timeline, review process, and exclusivity — and what it doesn't.